Organon Usa Inc patents expiration
1. Follistim patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767251 | ORGANON USA INC | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
Drugs and Companies using FOLLITROPIN ALFA/BETA ingredient
Market Authorisation Date: 29 September, 1997
Treatment: NA
Dosage: INJECTABLE;IM-SC
More Information on Dosage
FOLLISTIM family patents
2. Follistim Aq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767251 | ORGANON USA INC | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
| US5929028 | ORGANON USA INC | Liquid gonadotropin containing formulations |
Jan, 2018
(6 years ago) | |
| US7563763 | ORGANON USA INC | FSH and FSH variant formulations, products and methods |
Aug, 2019
(4 years ago) | |
| US7446090 | ORGANON USA INC | FSH formulation |
Aug, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-306) | Jun 28, 2013 |
Drugs and Companies using FOLLITROPIN ALFA/BETA ingredient
Market Authorisation Date: 26 August, 2005
Treatment: Method of treating infertility; A method for administering follicle stimulating hormone (fsh) for ovarian follicle or testicular stimulation in the human
Dosage: INJECTABLE;SUBCUTANEOUS
More Information on Dosage
FOLLISTIM AQ family patents
3. Raplon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5418226 | ORGANON USA INC | Monoquaternary 2,16-bispiperidinylandrostane derivatives |
Apr, 2013
(11 years ago) | |
Drugs and Companies using RAPACURONIUM BROMIDE ingredient
Market Authorisation Date: 18 August, 1999
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
RAPLON family patents